CASI Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of CASI Pharmaceuticals generated cash of -$19,967,000, which is more than the previous year. Cash used in financing activities reached the amount of -$907,000 last year. Net change in cash is therefore -$30,029,000.
Cash Flow
| 2014 | -3.99M | -466.32K | 0 |
|---|---|---|---|
| 2015 | -5.51M | -25.39K | 0 |
| 2016 | -6.02M | -64.78K | 28.04M |
| 2017 | -6.40M | -934.70K | 23.73M |
| 2018 | -28.58M | -21.77M | 92.26M |
| 2019 | -23.24M | -28.05M | 22.04M |
| 2020 | -25.88M | -20.71M | 47.15M |
| 2021 | -26.84M | -20.69M | 29.64M |
| 2022 | -21.08M | 31.15M | -3.26M |
| 2023 | -19.96M | -9.67M | -907K |
CASI Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 47.11M | 38.70M | 57.06M | 53.62M | 84.20M | 43.48M | 27.09M | 5.13M | 10.66M | 15.13M |
Operating activities | ||||||||||
Net income | -26.93M | -40.25M | -35.84M | -47.51M | -45.36M | -27.47M | -10.77M | -9.45M | -7.20M | -26.20M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 3.74M | 2.42M | 1.81M | 1.95M | 2.15M | 1.67M | 117.77K | 66.45K | 68.38K | 48.17K |
Stock-based compensation expense | 7.21M | 7.01M | 7.77M | 7.82M | 7.31M | 0 | 650.44K | 2.99M | 1.54M | 2.18M |
| Deferred income tax benefit | 7.21M | 7.01M | 7.77M | 7.82M | 7.31M | 0 | 650.44K | 2.99M | 1.54M | 2.18M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 2.83M | -3.17M | -5.15M | -3.35M | -1.29M | 0 | 0 | 0 | 23.72K | -23.72K |
Inventories | -9.73M | -4.23M | -551K | 3.18M | -4.41M | -283K | 0 | 0 | -4.63M | -10.15M |
Accounts payable | 1.14M | 1.06M | 1.49M | -1.54M | 4.00M | -1.09M | 849.36K | 180.52K | 129.47K | 352.17K |
Cash generated by operating activities | -19.96M | -21.08M | -26.84M | -25.88M | -23.24M | -28.58M | -6.40M | -6.02M | -5.51M | -3.99M |
Investing activities | ||||||||||
Purchases Of Investments | -51.75M | -7.42M | -12.40M | -83K | -14.03M | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -204K | -5.61M | -15.5M | -19.32M | -14.02M | -21.77M | -934.70K | -223.23K | -25.39K | -466.32K |
Acquisitions Net | 0 | 138K | 10K | 0 | 20M | -20.64M | 0 | 158.44K | 0 | 0 |
Cash generated by investing activities | -9.67M | 31.15M | -20.69M | -20.71M | -28.05M | -21.77M | -934.70K | -64.78K | -25.39K | -466.32K |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 32.5M | 46.15M | 182K | 87.99M | 23.87M | 28.14M | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -278K | -3.26M | 0 | -251K | 0 | -117K | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | -1.54M | -1.24M | -1.5M | 0 | 325.99K | 0 | 0 | 0 |
Cash used in financing activities | -907K | -3.26M | 29.64M | 47.15M | 22.04M | 92.26M | 23.73M | 28.04M | 0 | 0 |
Net Change In Cash | -30.02M | 8.40M | -18.36M | 3.44M | -30.58M | 40.71M | 16.39M | 21.96M | -5.53M | -4.46M |
Cash at end of period | 17.08M | 47.11M | 38.70M | 57.06M | 53.62M | 84.20M | 43.48M | 27.09M | 5.13M | 10.66M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |